FIA
TEVA icon

FNY Investment Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

FNY Investment Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$3K – 1053
2026
Q1 		$3K Buy
+100
New +$3.22K ﹤0.01% 645

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.63B AUM 45.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return
YDMI
Y.D. More Investments Ramat Gan, Israel $3.21B AUM 117.29% 1-Year Est. Return

FNY Investment Advisers's TEVA Position: Q2 2026 in Review

FNY Investment Advisers sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 10 shares.

FNY Investment Advisers first reported a position in TEVA in Q3 2018 and held it in 11 quarters. The position peaked at $516K in Q2 2025. 325 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • FNY Investment Advisers reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • FNY Investment Advisers sold 10 Teva Pharmaceuticals shares in Q2 2026.
  • FNY Investment Advisers first reported a position in Teva Pharmaceuticals in Q3 2018 and held it in 11 quarters.
  • FNY Investment Advisers's Teva Pharmaceuticals position peaked at $516K in Q2 2025.
  • 325 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.